CF
ALDX icon

Cantor Fitzgerald’s Aldeyra Therapeutics ALDX Stock Holding History

Cantor Fitzgerald’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Buy
+200,000
New +$344K ﹤0.01% 292
2023
Q2 		– Sell
-253,000
Closed -$2.51M – 574
2023
Q1 		$2.51M Buy
+253,000
New +$1.79M 0.05% 296

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Cantor Fitzgerald's ALDX Position: Q2 2026 in Review

Cantor Fitzgerald opened a new position in Aldeyra Therapeutics (ALDX) in Q2 2026: 200,000 shares worth $426K. The stake represents ﹤0.01% of the portfolio and ranks #292 among its holdings. This is a return to the name: Cantor Fitzgerald previously reported a position in ALDX as recently as Q1 2023.

Cantor Fitzgerald first reported a position in ALDX in Q1 2023 and has held it in 2 quarters since. The position peaked at $2.51M in Q1 2023. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Cantor Fitzgerald held 200,000 shares of Aldeyra Therapeutics worth $426K as of Q2 2026.
  • Aldeyra Therapeutics was a new Cantor Fitzgerald position in Q2 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #292 holding.
  • Cantor Fitzgerald first reported a position in Aldeyra Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • Cantor Fitzgerald's Aldeyra Therapeutics position peaked at $2.51M in Q1 2023.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.